Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote & News

Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 344 4190

Website: acumenpharm.com

Address:

1210-1220 Washington St., Suite 210, Newton, United States

mhaven2020 Jan. 9 at 7:27 PM

$ASPI $CYCN $UAMY $QBTS all look pretty good right now. $ABOS needs to follow suit. Follow for more!

0 · Reply

mhaven2020 Jan. 9 at 7:10 PM

$CYCN the daily chart looks like it could be gearing up for a move back to $3. $ABOS $IOVA $UAMY

1 · Reply

Stockley_Bulbousberries Jan. 8 at 3:52 PM

$ABOS Not quite sure why the drop, other than some low-level insider selling for tax purposes. Either way, a good opportunity to load.

0 · Reply

topstockalerts Jan. 6 at 3:22 AM

After Hours Top Gainers PT2 $BSCR $VRME $ABOS $GNLX $UFG

0 · Reply

SusQSmallMouth Jan. 6 at 1:56 AM

$ABOS suprised this board is mostly crickets. Ive been in this for a year now with an avg around 1.50. I was actaully shocked it was one of the top picks in bio games on X if anyone follows that game...just for fun type game. Shocked because no one seems to talk about this company much. Guess that's probably for the best. What's everyones thoughts for 2026 here?

1 · Reply

Stockley_Bulbousberries Jan. 5 at 6:00 PM

$ABOS https://news.northwestern.edu/stories/2025/12/nu-9-halts-alzheimers-disease-in-animal-model-before-symptoms-begin

0 · Reply

CloudCuckooC Dec. 25 at 11:24 AM

$ABOS Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Execution pathways should simplify rather than expand in complexity from here. Missed checkpoints may compound into higher capital costs. Overall, the trajectory is less about vision and more about proving the operating model works.

0 · Reply

GoldStandardG Dec. 24 at 11:48 AM

$ABOS Current positioning will be tested as strategic priorities translate into measurable operating outcomes. Execution slippage remains the dominant downside risk.

0 · Reply

SuperGreenToday Dec. 24 at 2:09 AM

$ABOS Share Price: $2.16 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.71 – $0.87 Potential Upside: 58% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

mhaven2020 Dec. 19 at 3:48 PM

$ABOS Here are some market movers that have occurred 6 times or more in the last 6 months. Happy hunting! Follow me on X and YouTube for more. I'm closing out things, tax harvesting, locking profits. Time to slow down the trade cycle for the rest of the year; at least for me. I will be doing some research on all of these and some other daily scan results to put a few videos together. $IOVA $AGEN $SAVA Have a great weekend!

0 · Reply

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript

Sep 2, 2025, 9:28 PM EDT - 4 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 4:00 PM EDT - 5 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2025, 2:46 PM EDT - 5 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 5 months ago

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:00 PM EDT - 5 months ago

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 15, 2025, 7:00 AM EDT - 6 months ago

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

Jul 10, 2025, 8:00 AM EDT - 6 months ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

May 13, 2025, 10:11 AM EDT - 8 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:00 PM EDT - 9 months ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 6, 2025, 4:00 PM EDT - 9 months ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 2, 2025, 7:00 AM EDT - 10 months ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 10:05 AM EDT - 10 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:00 PM EDT - 10 months ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:48 AM EDT - 10 months ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 12, 2025, 8:00 AM EDT - 11 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Nov 26, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:17 PM EST - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Sep 30, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 3, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 11:17 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 8:38 PM EDT - 1 year ago

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 14, 2024, 12:46 PM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 16, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 26, 2024, 10:45 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 12, 2024, 4:00 PM EDT - 2 years ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 8:50 AM EST - 2 years ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 2 years ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 4, 2024, 4:15 PM EST - 2 years ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 4:29 PM EST - 2 years ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

mhaven2020 Jan. 9 at 7:27 PM

$ASPI $CYCN $UAMY $QBTS all look pretty good right now. $ABOS needs to follow suit. Follow for more!

0 · Reply

mhaven2020 Jan. 9 at 7:10 PM

$CYCN the daily chart looks like it could be gearing up for a move back to $3. $ABOS $IOVA $UAMY

1 · Reply

Stockley_Bulbousberries Jan. 8 at 3:52 PM

$ABOS Not quite sure why the drop, other than some low-level insider selling for tax purposes. Either way, a good opportunity to load.

0 · Reply

topstockalerts Jan. 6 at 3:22 AM

After Hours Top Gainers PT2 $BSCR $VRME $ABOS $GNLX $UFG

0 · Reply

SusQSmallMouth Jan. 6 at 1:56 AM

1 · Reply

Stockley_Bulbousberries Jan. 5 at 6:00 PM

$ABOS https://news.northwestern.edu/stories/2025/12/nu-9-halts-alzheimers-disease-in-animal-model-before-symptoms-begin

0 · Reply

CloudCuckooC Dec. 25 at 11:24 AM

0 · Reply

GoldStandardG Dec. 24 at 11:48 AM

$ABOS Current positioning will be tested as strategic priorities translate into measurable operating outcomes. Execution slippage remains the dominant downside risk.

0 · Reply

SuperGreenToday Dec. 24 at 2:09 AM

0 · Reply

mhaven2020 Dec. 19 at 3:48 PM

0 · Reply

mhaven2020 Dec. 18 at 5:37 PM

$ABOS $IOVA $VERO and whoever else cares, I am dropping this trading journal on Amazon. It has Advanced logs, simple logs and graphics tracking. I'll put some info up when it is published. Check out our website to sign up for Alerts. Follow on X and Youtube for more! $FOXX

1 · Reply

mhaven2020 Dec. 16 at 4:22 PM

$ABOS $IOVA $IRWD pretty much all the way out of these. Dumped into $VERO for a few days

0 · Reply

mhaven2020 Dec. 15 at 4:48 PM

$ABOS closed some at 2.12 and 2.08... stilp holding a few hundred but im mostly out of here. Let the rest ride for another week. $IRWD still winning.

0 · Reply

Stockley_Bulbousberries Dec. 15 at 2:34 PM

$ABOS

0 · Reply

jacksparo Dec. 13 at 4:59 PM

$ABOS I shared this in my email group and so far it is doing great. This one among my monthly regular updated stocks until I achieve my goal in it.

0 · Reply

isaacwilliams33 Dec. 12 at 9:09 PM

$DWTX $ABOS radar pick ups

0 · Reply

Johndoe456 Dec. 12 at 6:56 PM

$ABOS

0 · Reply

jacksparo Dec. 12 at 3:04 PM

$ABOS VIP pick for this week ... Enjoy my email team!

0 · Reply

jdkd4 Dec. 12 at 3:03 PM

$ABOS nice!

1 · Reply

mhaven2020 Dec. 8 at 8:50 PM

$ABOS still holding. Also $IOVA and $INMB for a few days. Sign up for alerts on our website. Follow me on X and YouTube for more. I tried to cram so much in my last video and had two tickers and The Trade Commando system in there. Future videos will be on one ticker with extensive details. Any tickers you want me to cover?

0 · Reply

mhaven2020 Dec. 5 at 7:18 PM

$ABOS thanks for the dip. Bought more.

0 · Reply

SannieVerraderlijk Dec. 5 at 9:56 AM

$ABOS This is a sleeper, trading at 20ish million EV, huge indication and good scientific rationale. Could see runup into eoy 26

0 · Reply

Market Cap	112.67M
Revenue (ttm)	0.00
Net Income (ttm)	-102.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.33

Volume	305,600
Avg Vol	183,626
Day's Range	N/A - N/A
Shares Out	60.57M
Stochastic %K	58%
Beta	0.23
Analysts	Strong Sell
Price Target	$6.50